Search for 'an:"1811"'

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(3):423-9. , Formato Vancouver: Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9.

Place Hold on Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

Current Challenges in Cancer Treatment.

By Zugazagoitia, Jon | Guedes, Cristiano | Ponce Aix, Santiago | Ferrer, Irene | Molina Pinelo, Sonia | Paz-Ares Rodríguez, Luis. Clinical therapeutics, 2016 . 38(7):1551-66. , Formato Vancouver: Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina Pinelo S, Paz Ares L. Current Challenges in Cancer Treatment. Clin Ther. 2016 Jul;38(7):1551-66.

Place Hold on Current Challenges in Cancer Treatment.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(8):1573-9. , Formato Vancouver: Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9.

Place Hold on Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

By Rodríguez Garzotto, Analía | Díaz García, C. Vanesa | Agudo López, Alba | Prieto García, Elena | Ponce Aix, Santiago | López Martín, José Antonio | Paz-Ares Rodríguez, Luis | Iglesias Docampo, Lara | Agulló Ortuño, María Teresa. Medical oncology (Northwood, London, England), 2016 . 33(10):105. , Formato Vancouver: Rodríguez Garzotto A, Díaz García CV, Agudo López A, Prieto García E, Ponce S, López Martín JA et al. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol. 2016 Oct;33(10):105.

Place Hold on Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

By Molina Pinelo, Sonia | Paz-Ares Rodríguez, Luis. Oncotarget, 2016 . 7(33):52849-52861. , Formato Vancouver: Usó M, Jantus Lewintre E, Bremnes RM, Calabuig S, Blasco A, Pastor E et al. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Oncotarget. 2016 Aug 16;7(33):52849-52861.

Place Hold on Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

By Paz-Ares Rodríguez, Luis. The Lancet. Oncology, 2016 . 17(5):577-89. , Formato Vancouver: Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89.

Place Hold on Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

By Agulló Ortuño, María Teresa | Díaz García, C. Vanesa | Agudo López, Alba | Pérez, Carlos | Cortijo, Ana | Paz-Ares Rodríguez, Luis | Pozo Rodríguez, Francisco | Cortés-Funes Castro, Hernán | López Martín, José Antonio. Journal of cancer research and clinical oncology, 2015 . 141(1):43-53. , Formato Vancouver: Agulló Ortuño MT, Díaz García CV, Agudo López A, Pérez C, Cortijo A, Paz Ares L et al. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53.

Place Hold on Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

By Paz-Ares Rodríguez, Luis. The Lancet. Oncology, 2015 . 16(3):328-37. , Formato Vancouver: Paz Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar;16(3):328-37.

Place Hold on Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.

By Coronado, C. | Cortés-Funes Castro, Hernán | López Martín, Ana | Paz-Ares Rodríguez, Luis. Cancer chemotherapy and pharmacology, 2013 . 72(1):75-83. , Formato Vancouver: Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C et al. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83.

Place Hold on Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.

Bases farmacológicas del tratamiento antineoplásico

By Paz-Ares Rodríguez, Luis. Madrid: Grupo Aula Médica, 1999 . p. 127-139 , Formato Vancouver: Paz-Ares L, Izquierdo MA. Bases farmacológicas del tratamiento antineoplásico. En: Cortés-Funes H, Díaz-Rubio E, García Conde J, Germà Lluch JR, Guillem Porta V, López López JJ, et al., editores. Oncología médica. Madrid: Grupo Aula Médica, 1999. p. 127-39.

Place Hold on Bases farmacológicas del tratamiento antineoplásico

Quimioterapia: Agentes, combinaciones, mecanismos de resistencia, nuevos agentes

By Paz-Ares Rodríguez, Luis. Madrid: Grupo Aula Médica, 1999 . p. 140-163 , Formato Vancouver: Izquierdo MA, Paz-Ares L. Quimioterapia: Agentes, combinaciones, mecanismos de resistencia, nuevos agentes. En: Cortés-Funes H, Díaz-Rubio E, García Conde J, Germà Lluch JR, Guillem Porta V, López López JJ, et al., editores. Oncología médica. Madrid: Grupo Aula Médica, 1999. p. 140-63.

Place Hold on Quimioterapia: Agentes, combinaciones, mecanismos de resistencia, nuevos agentes

Ensayos clínicos en oncología

By Alonso, S. | Paz-Ares Rodríguez, Luis. Madrid: Grupo Aula Médica, 1999 . p. 310-319 , Formato Vancouver: Alonso S, García-Carbonero R, Paz-Ares L. Ensayos clínicos en oncología. En: Cortés-Funes H, Díaz-Rubio E, García Conde J, Germà Lluch JR, Guillem Porta V, López López JJ, et al., editores. Oncología médica. Madrid: Grupo Aula Médica, 1999. p. 310-9

Place Hold on Ensayos clínicos en oncología

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Paz-Ares Rodríguez, Luis. Investigational New Drugs, 2012 . 30(2):729-40. , Formato Vancouver: Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr;30(2):729-40.

Place Hold on Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

By Ciruelos Gil, Eva María | Cortés-Funes Castro, Hernán | Paz-Ares Rodríguez, Luis. Medical Oncology, 2012 . 29(3):2240-50. , Formato Vancouver: Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, et al. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function. Med Oncol. 2012 Sep;29(3):2240-50.

Place Hold on Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

By Cortés-Funes Castro, Hernán | López Martín, José Antonio | Paz-Ares Rodríguez, Luis. British Journal of Cancer, 2012 . 106(8):1379-85. , Formato Vancouver: Yap TA, Cortés-Funes H, Shaw H, Rodríguez R, Olmos D, Lal R, et al. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br J Cancer. 2012 Apr 10;106(8):1379-85.

Place Hold on First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

By Paz-Ares Rodríguez, Luis | Sánchez, José Miguel. The Lancet Oncology, 2012 . 13(3):239-46. , Formato Vancouver: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46.

Place Hold on Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure.

By Paz-Ares Rodríguez, Luis. Clinical Cancer Research, 2012 . 18(11):3170-9. , Formato Vancouver: Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res. 2012 Jun 1;18(11):3170-9.

Place Hold on Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure.

Tratamiento actual y perspectivas futuras del carcinoma de próstata hormonorresistente

By Paz-Ares Rodríguez, Luis. . p. 67-69. , Formato Vancouver: Paz-Ares Rodríguez L. Tratamiento actual y perspectivas futuras del carcinoma de próstata hormonorresistente. En: Sociedad Española de Oncología Médica. Ponencias X Congreso Nacional SEOM: 23 al 25 de junio de 2005, Zaragoza, Auditorio-Palacio de Congresos. Zaragoza: SEOM; 2005. p. 67-9

Place Hold on Tratamiento actual y perspectivas futuras del carcinoma de próstata hormonorresistente